Abstract Number: 1049 • ACR Convergence 2020
Effects of Nintedanib in Patients with Progressive Fibrosing Autoimmune Disease-related Interstitial Lung Diseases (ILDs) in the INBUILD Trial: Subgroups by HRCT Pattern
Background/Purpose: In the INBUILD trial, nintedanib reduced the rate of decline in forced vital capacity (FVC) over 52 weeks compared with placebo in patients with…Abstract Number: 1161 • ACR Convergence 2020
Perspectives of Radiologist Physicians in the Imaging of Chronic Nonbacterial Osteomyelitis
Background/Purpose: Radiological imaging is integral to the diagnosis of chronic nonbacterial osteomyelitis (CNO) and has been included as a central component in suggested diagnostic criteria…Abstract Number: 568 • 2019 ACR/ARP Annual Meeting
Understanding mNY Radiograph Score Discordance in Axial Spondyloarthritis Clinical Trials Using Imaging Criteria for Subject Eligibility
Background/Purpose: Axial spondyloarthritis (axSpA) is typically radiographically confirmed on the sacroiliac joint (SIJ) as assessed by the modified New York (mNY) criteria. In clinical trials,…Abstract Number: 618 • 2019 ACR/ARP Annual Meeting
Factors Associated with Complete Spinal Fusion in Patients with Ankylosing Spondylitis
Background/Purpose: Most patients with ankylosing spondylitis (AS) do not develop complete spinal fusion. The purpose of this study was to compare patients with complete spinal…Abstract Number: 938 • 2019 ACR/ARP Annual Meeting
TNF Inhibitors Reduce Spinal Radiographic Progression in Axial Spondyloarthritis by Mechanisms Associated with but Also Independent of Disease Activity
Background/Purpose: Recent observational data suggest that TNFi reduce spinal radiographic progression in radiographic axial spondyloarthritis (r-axSpA) mostly by inhibiting disease activity1. Yet, resolution on the…Abstract Number: 1554 • 2019 ACR/ARP Annual Meeting
Effect of Secukinumab on Radiographic Progression Through 2 Years in Patients with Active Psoriatic Arthritis: End-of-study Results from a Phase III Study
Background/Purpose: Secukinumab (SEC) provided sustained efficacy, inhibition of radiographic progression, and stable safety profile over 52 Weeks (Wks) in patients (pts) with psoriatic arthritis (PsA)…Abstract Number: 2185 • 2019 ACR/ARP Annual Meeting
MRI-detected Abnormalities in Prediction Models of Incident Radiographic Knee Osteoarthritis over 10 Years of Follow-up
Background/Purpose: MRI Osteoarthritis Knee Score (MOAKS) is a semi-quantitative scoring system used to assess MRI-detected structural abnormalities including over 100 raw scores representing multiple joint…Abstract Number: 561 • 2018 ACR/ARHP Annual Meeting
U-Act-Early Trial 3 Years Follow-up: Radiographic Joint Damage and Use of Bdmards over 5 Years in Early RA Patients Treated-to-Target with Strategies Initiating Tocilizumab, Methotrexate or Their Combination
Background/Purpose: The U-Act-Early trial was a 2-year multicentre, double-blind, randomized, placebo-controlled trial in early (DMARD-naïve) RA patients treated to the target of remission, with step-up…Abstract Number: 1443 • 2018 ACR/ARHP Annual Meeting
Ultrasonographic Criteria for the Diagnosis of Erosive Rheumatoid Arthritis Disease Using Osteoarthritic Patients As Controls Compared to Validated Radiographic Criteria
Background/Purpose: Rheumatoid arthritis (RA) is the most prevalent chronic inflammatory joint disease (1,2) responsible for structural damage. Radiography (RX) is considered as the gold standard…Abstract Number: 1444 • 2018 ACR/ARHP Annual Meeting
Optimization of Ultrasonographic Examination for the Diagnosis of Erosive Rheumatoid Arthritis Versus Erosive Osteoarthritis with Radiography Considered As Gold Standard
Background/Purpose: Rheumatoid arthritis (RA) is the most prevalent chronic inflammatory joint disease (1,2) responsible for structural damage. Radiography (RX) is considered as the gold standard…Abstract Number: 1457 • 2018 ACR/ARHP Annual Meeting
Association between Disease Activity and Radiographic Progression in the Current Treat-to-Target Paradigm of Rheumatoid Arthritis: Real World Data from the Dutch Rheumatoid Arthritis Monitoring (DREAM) Registry
Background/Purpose: Recent studies suggested a disconnect between disease activity and radiographic damage in rheumatoid arthritis (RA) patients treated with more aggressive treatment (1). Therefore, the…Abstract Number: 2806 • 2017 ACR/ARHP Annual Meeting
Integrated Longitudinal Analysis Increases Precision and Reduces Bias: A Comparative 5-Year Analysis in the DESIR Cohort
Background/Purpose: Evaluation of imaging is important in spondyloarthritis (SpA) research, but loss to follow up often jeopardizes interpretation of the evaluation. The Interpretation may further…Abstract Number: 533 • 2017 ACR/ARHP Annual Meeting
Assessment of Radiographic Progression in Patients with Rheumatoid Arthritis Treated with Tofacitinib: Data from an Open-Label Long-Term Extension Study over 3 Years
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. The long-term safety and clinical efficacy of tofacitinib 5 and 10 mg…Abstract Number: 1366 • 2017 ACR/ARHP Annual Meeting
Evaluation of Synovial Fluid 14-3-3η Protein As a Marker of Joint Damage in Rheumatoid Arthritis Patients
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease that results in severe joint damage and physical disability, therefore, the discovery of new marker(s) for…Abstract Number: 2437 • 2017 ACR/ARHP Annual Meeting
Long-Term Effect of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, on Radiographic Progression in Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment: Results of a Global Phase 3 Trial
Background/Purpose: In the SIRROUND-D study, sirukumab (SIR), a human monoclonal antibody that selectively binds to the IL-6 cytokine with high affinity, significantly reduced radiographic progression…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- 9
- Next Page »